title: t(8;16) AML developed subsequent to breast cancer therapy.
abstract: We report a breast cancer patient who developed acute myeloid leukemia (AML) one year following her adjuvant chemotherapy consisting of cyclophosphamide, adriamycin and 5-fluorouracil. Cytogenetic examination of bone marrow samples resulted in t(8;16)(p11.2;p13.3), which is a chromosome rearrangement observed in de novo and treatment related AML M4/M5 with a poor prognosis.
authors.affiliation: Baskent University Faculty of Medicine, Department of Medical Genetics, Ankara, Turkey. feridesahin@hotmail.com
authors.forename: Feride Iffet
authors.initials: FI
authors.lastname: Sahin
authors.forename: Zerrin
authors.initials: Z
authors.lastname: Yilmaz
authors.forename: Sema
authors.initials: S
authors.lastname: Karakuş
authors.forename: Salih
authors.initials: S
authors.lastname: Boğa
authors.forename: Zefer
authors.initials: Z
authors.lastname: Akçali
authors.forename: Beyhan
authors.initials: B
authors.lastname: DemIrhan
mesh_terms: D000077384:Anastrozole; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D001853:Bone Marrow / Q000473:pathology; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery; D018275:Carcinoma, Lobular / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery; D017024:Chemotherapy, Adjuvant / Q000009:adverse effects; D002885:Chromosomes, Human, Pair 16 / Q000235:genetics / Q000648:ultrastructure*; D002898:Chromosomes, Human, Pair 8 / Q000235:genetics / Q000648:ultrastructure*; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D003561:Cytarabine / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D004967:Estrogens; D017809:Fatal Outcome; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage; D015479:Leukemia, Myelomonocytic, Acute / Q000139:chemically induced / Q000188:drug therapy / Q000235:genetics / Q000473:pathology*; D015411:Mastectomy, Modified Radical; D008875:Middle Aged; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D009378:Neoplasms, Multiple Primary / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery; D016609:Neoplasms, Second Primary / Q000188:drug therapy / Q000235:genetics / Q000473:pathology*; D009570:Nitriles / Q000627:therapeutic use; D018714:Radiotherapy, Adjuvant; D014178:Translocation, Genetic; D014230:Triazoles / Q000627:therapeutic use
chemical_list: D018931:Antineoplastic Agents, Hormonal; D004967:Estrogens; D009570:Nitriles; D014230:Triazoles; D003561:Cytarabine; D000077384:Anastrozole; D004317:Doxorubicin; D003520:Cyclophosphamide; D005472:Fluorouracil; D015255:Idarubicin